<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of <z:chebi fb="0" ids="8871">risperidone</z:chebi> in the treatment of <z:hpo ids='HP_0000718'>aggression</z:hpo>, <z:hpo ids='HP_0000713'>agitation</z:hpo>, and <z:hpo ids='HP_0000709'>psychosis</z:hpo> in elderly nursing-home patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHOD: Elderly patients with a <z:chebi fb="4" ids="38624">DSM</z:chebi>-IV diagnosis of <z:hpo ids='HP_0000726'>dementia</z:hpo> of the Alzheimer's type, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, or a combination of the 2 (i.e., mixed <z:hpo ids='HP_0000726'>dementia</z:hpo>) and significant <z:hpo ids='HP_0000718'>aggressive behaviors</z:hpo> were randomized to receive, for a period of 12 weeks, a flexible dose of either placebo or <z:chebi fb="0" ids="8871">risperidone</z:chebi> solution up to a maximum of 2 mg/day </plain></SENT>
<SENT sid="2" pm="."><plain>Outcome measures were the Cohen-Mansfield <z:hpo ids='HP_0000713'>Agitation</z:hpo> Inventory (CMAI), the Behavioral Pathology in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> (BEHAVE-AD) rating scale, and the Clinical Global Impression of Severity (CGI-S) and of Change (CGI-C) scales </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 345 patients were randomized to treatment with <z:chebi fb="0" ids="8871">risperidone</z:chebi> or placebo, and 337 patients received at least one dose of study drug </plain></SENT>
<SENT sid="4" pm="."><plain>The trial was completed by 67% of patients in the placebo group and 73% of patients in the <z:chebi fb="0" ids="8871">risperidone</z:chebi> group </plain></SENT>
<SENT sid="5" pm="."><plain>The mean +/- SE dose of <z:chebi fb="0" ids="8871">risperidone</z:chebi> was 0.95 +/- 0.03 mg/day </plain></SENT>
<SENT sid="6" pm="."><plain>The primary endpoint of the study, the difference from baseline to endpoint in CMAI total <z:hpo ids='HP_0000718'>aggression</z:hpo> score, showed a significant reduction in <z:hpo ids='HP_0000718'>aggressive behavior</z:hpo> for <z:chebi fb="0" ids="8871">risperidone</z:chebi> versus placebo (p &lt;.001) </plain></SENT>
<SENT sid="7" pm="."><plain>A similar improvement was also seen for the CMAI total non-<z:hpo ids='HP_0000718'>aggression</z:hpo> subscale (p &lt;.002) and for the BEHAVE-AD total (p &lt;.001) and <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> symptoms subscale (p =.004) </plain></SENT>
<SENT sid="8" pm="."><plain>At endpoint, the CGI-S and the CGI-C scores indicated a significantly greater improvement with <z:chebi fb="0" ids="8871">risperidone</z:chebi> compared with placebo (p &lt;.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Overall, 94% and 92% of the <z:chebi fb="0" ids="8871">risperidone</z:chebi> and placebo groups, respectively, reported at least 1 adverse event </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0001262'>Somnolence</z:hpo> and <z:hpo ids='HP_0000010'>urinary tract infection</z:hpo> were more common with <z:chebi fb="0" ids="8871">risperidone</z:chebi> treatment, whereas <z:hpo ids='HP_0000713'>agitation</z:hpo> was more common with placebo </plain></SENT>
<SENT sid="11" pm="."><plain>There was no significant difference in the number of patients who reported <z:hpo ids='HP_0002071'>extrapyramidal symptoms</z:hpo> between the <z:chebi fb="0" ids="8871">risperidone</z:chebi> (23%) and placebo (16%) groups </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Treatment with low-dose (mean = 0.95 mg/day) <z:chebi fb="0" ids="8871">risperidone</z:chebi> resulted in significant improvement in <z:hpo ids='HP_0000718'>aggression</z:hpo>, <z:hpo ids='HP_0000713'>agitation</z:hpo>, and <z:hpo ids='HP_0000709'>psychosis</z:hpo> associated with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>